Targeting Heat Shock Transcription Factor 4 Enhances the Efficacy of Cabozantinib and Immune Checkpoint Inhibitors in Renal Cell Carcinoma
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26041776 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Saeki Saito und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Anilides, Pyridines, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kaken Pharmaceutical (Japan), the Kodama Memorial Fund for Medical Research, Japan Society for the Promotion of Science, KAKENHI.
Abstract (Originalsprache)
Recently, immune checkpoint inhibitors (ICIs) and cabozantinib, a tyrosine kinase inhibitor (TKI), have been used to treat renal cell carcinoma (RCC); the combination of these agents has become a standard treatment for RCC. TKIs generally target vascular endothelial growth factor. However, cabozantinib is characterized by its targeting of MET. Therefore, cabozantinib can be used as a late-line therapy for TKI-resistant RCC. According to data from The Cancer Genome Atlas (TCGA), heat shock transcription factor 4 (HSF4) expression is higher in RCC tissues than in normal renal tissues. HSF4 binds to the MET promoter in colorectal carcinoma to enhance MET expression and promote tumor progression. However, the functional role of HSF4 in RCC is unclear. We performed loss-of-function assays of HSF4, and our results showed that HSF4 knockdown in RCC cells significantly decreased cell functions. Moreover, MET expression was decreased in HSF4-knockdown cells but elevated in sunitinib-resistant RCC cells. The combination of cabozantinib and HSF4 knockdown reduced cell proliferation in sunitinib-resistant cells more than each monotherapy alone. Furthermore, HSF4 knockdown combined with an ICI showed synergistic suppression of tumor growth in vivo. Overall, our strategy involving HSF4 knockdown may enhance the efficacy of existing therapies, such as cabozantinib and ICIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.
- Department of Pathology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan.
ORCID-Profile: Hirofumi Yoshino, Seiya Yokoyama, Junya Arima, Shuichi Tatarano
Förderung
- Kaken Pharmaceutical (Japan)
- the Kodama Memorial Fund for Medical Research
- Japan Society for the Promotion of Science, KAKENHI
- Kodama Memorial Fund for Medical Research
Zitieren
APA
Saito, S., Yoshino, H., Yokoyama, S., Tominaga, M., Li, G., Arima, J., Kawahara, I., Fukuda, I., Mitsuke, A., Sakaguchi, T., Inoguchi, S., Matsushita, R., Yamada, Y., Tatarano, S., Tanimoto, A., & Enokida, H. (2025). Targeting Heat Shock Transcription Factor 4 Enhances the Efficacy of Cabozantinib and Immune Checkpoint Inhibitors in Renal Cell Carcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26041776
Vancouver
Saito S, Yoshino H, Yokoyama S, Tominaga M, Li G, Arima J, et al. Targeting Heat Shock Transcription Factor 4 Enhances the Efficacy of Cabozantinib and Immune Checkpoint Inhibitors in Renal Cell Carcinoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26041776
BibTeX
@article{Saito2025,
author = {Saito, Saeki and Yoshino, Hirofumi and Yokoyama, Seiya and Tominaga, Mitsuhiko and Li, Gang and Arima, Junya and Kawahara, Ichiro and Fukuda, Ikumi and Mitsuke, Akihiko and Sakaguchi, Takashi and Inoguchi, Satoru and Matsushita, Ryosuke and Yamada, Yasutoshi and Tatarano, Shuichi and Tanimoto, Akihide and Enokida, Hideki},
title = {Targeting Heat Shock Transcription Factor 4 Enhances the Efficacy of Cabozantinib and Immune Checkpoint Inhibitors in Renal Cell Carcinoma},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26041776}
}
EUVIMED